GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Unigene Gets Funding for Novel Peptide Hormone Therapies

  • Unigene Laboratories received a $900,000 funding to advance it’s discovery program related to therapeutic peptide hormones. The phase II SBIR grant from the National Institute for Diabetes and Digestive Kidney Diseases will be provided over two years.

    In 2003, Unigene received a phase I grant, which allowed the company to utilize the technology it developed in collaboration with the University of South Florida to establish a procedure for identifying such peptides in various plant or animal tissues.

    "An increasing number of peptides are being shown to play essential roles in fundamental human metabolic processes, yet only a small number of these have already been commercialized,” states Ronald S. Levy, M.D., executive vp of Unigene. “This program can create additional opportunities for the utilization of Unigene's peptide manufacturing and delivery technologies, while enabling us to obtain additional patent protection on the novel peptides themselves."


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »